Achieving targeted delivery of anticancer drugs following the administration of current therapies remains a challenge that needs to be addressed. Metallic nanoparticles (NPs) offer potential solutions to this issue. This study focuses specifically on utilizing gold nanoparticles (AuNPs) as carriers for the anticancer drug Doxorubicin (DOX), resulting in the creation of a nanohybrid known as DOX@AuNPs. The effectiveness of this nanocomposite was assessed through the SRP assay on MCF7, a breast cancer cell line, at different incubation periods (24 hours, 48 hours, and 72 hours). To analyze the DOX@AuNPs nanohybrid, UV-visible spectroscopy, transmission electron microscopy (TEM), and fluorescence spectroscopy were employed. The AuNPs and DOX@AuNPs nanohybrid displayed spherical shapes, with sizes of approximately 10±2 nm and 13±2 nm, respectively. Notably, the DOX@AuNPs nanohybrid demonstrated enhanced anticancer activity against the MCF7 cell line compared to free DOX. These findings indicate that AuNPs serve as effective carriers for Doxorubicin in the treatment of breast cancer.